Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-03-28
1998-12-15
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31135
Patent
active
058498001
ABSTRACT:
Methods for treating patients with viral infection with pharmaceutical agents are disclosed. In one embodiment, the virus is Hepatitis C and the pharmaceutical agent is amantadine. The methods of the present invention can be used in patients that have not responded to or cannot tolerate interferon treatment, as well as patients under the age of eighteen.
REFERENCES:
patent: 3310469 (1967-03-01), Paulshock et al.
patent: 4557934 (1985-12-01), Cooper
patent: 4895727 (1990-01-01), Allen
patent: 5427909 (1995-06-01), Okamoto et al.
patent: 5428145 (1995-06-01), Okamoto et al.
patent: 5436126 (1995-07-01), Wang
patent: 5437974 (1995-08-01), Ryan et al.
patent: 5502080 (1996-03-01), Hitzig
patent: 5514539 (1996-05-01), Bukh et al.
patent: 5527669 (1996-06-01), Resnick et al.
patent: 5529914 (1996-06-01), Hubbell et al.
patent: 5552310 (1996-09-01), Yoshikura et al.
patent: 5573934 (1996-11-01), Hubbell et al.
patent: 5574132 (1996-11-01), Lacroix et al.
patent: 5580718 (1996-12-01), Resnick et al.
patent: 5582968 (1996-12-01), Wang et al.
patent: 5595868 (1997-01-01), Habets et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5599998 (1997-02-01), Kraus
patent: 5601844 (1997-02-01), Kagayama et al.
Stevens et al., "Epidemiology of Hepatitis C Virus: A Preliminary Study in Volunteer Blood Donors," JAMA 263:49-53 (1990).
Choo et al., "Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis," Science 244:359-362 (1989).
Alter et al., "The Natural History of Community-Acquired Hepatitis C in the United States," N. Engl J Med 327(27):1899-1905 (1992).
Tong et al., "Clinical Outcomes After Transfusion-Associated Hepatitis C," N Engl J Med 332:1463-1466 (1995).
Liang et al., "Viral Pathogenesis of Hepatocellular Carcinoma in the United States," Hepatology 18:1326-1333 (1993).
Tsukuma et al., "Risk Factors For Hepatocellular Carcinoma Among Patients With Chronic Liver Disease," N Engl J Med 328:1797-1801 (1993).
Ascher et al., "Liver Transplantation For Hepatitis C Virus-Related Cirrhosis," Hepatology 20(suppl):24-27 (1994).
Davis et al., "Treatment of Chronic Hepatitis C With Recombinant Interferon ALFA A: A Multicenter Randomized, Controlled Trial," N Engl J Med 321(22):1501-1506 (1989).
Lunel et al., "Cryoglobulinemia in Chronic Liver Diseases: Role of Hepatitis C Virus and Liver Damage," Gastroenterology 106:1291-1300 (1994).
Misiani et al., "Interferon ALFA-2a Therapy In Cryglobulinemia Associated Hepatitis C Virus," N Engl J Med 330:751-756 (1994).
DeCastro et al., Hepatitis C Virus Antibodies and Liver Disease in Patients with Porphyria Cutanea Tarda, Hepatology 17:551-557 (1993).
Wilson et al., "Mooren's Corneal Ulcers and Hepatitis C Virus Infection," N Engl J Med 329:62 (letter) (1993).
Pawlotsky et al., "Immunological Disorders In C Virus Active Hepatitis; A Prospective Case-Control Study," Hepatology 19:841-848 (1994).
Di Bisceglie et al., "Recombinant Interferon Alfa Therapy For Chronic Hepatitis C," N Engl J Med 321:1506-1510 (1989).
Tine et al., "Interferon For Non-A, Non-B Chronic Hepatitis: A Meta-Analysis of Radomised Clinical Trials," J Hepatol 13:192-199 (1991).
Taliani et al., "One Course Versus Two Courses of Recombinant Alpha Interferon In Chronic C Hepatitis," Arch Virol Suppl 4:294-298 (1992).
Marcellin et al., "Lack of Benefit of Escalating Dosage of Interferon Alfa In Patients With Chronic Hepatitis C," Gastroenterology 109:156-165 (1995).
Poynard et al., "A Comparison of Three Interferon Alfa-2b Regimens For The Long-Term Treatment of Chronic Non-A, Non-B Hepatitis," N Engl J Med 332:1457-1462, (1995).
Aoki and Sitar, "Clinical Pharmacokinetics of Amantadine Hydrochloride," Clin Pharm 14:35-51 (1988).
Skehel et al., "On The Mechanism of Inhibition of Influenza Virus Replication By Amantadine Hydrochloride," J Gen Virol 38:97-110 (1978).
Stokes et al., "Effects of Short-Term Corticosteroid Therapy In Patients With Chronic Non-A, Non-B Hepatitis (NANB)," Gastroenterology 92:1783 (abstract) (1993).
Di Bisceglie et al., "A Pilot Study of Ribavirin Therapy For Chronic Hepatitis C," Hepatology 16:649-654 (1992).
Hay and Zambon, "Multiple Actions of Amantadine Against Influenza Viruses," Dev. Mol. Virol. 4:301-315(1984).
Fiedler, Lexicon Der Hilfastoffe Fur Pharmazie, Kosmetik Und Angrezende Gebiete (Lexicon of Adjuvants for Pharmacy, Cosmetics an Related Areas) 191-195 (1971).
Urdea et al., "Branched DNA Amplification Multimers For The Sensitive, Direct Detection of Human Hepatitis Viruses," Nucl Acids Sym 24:197-200, (abstract) (1991).
Lau et al., "Significance of Serum Hepatitis C Virus RNA Levels In Chronic Hepatitis C," Lancet 341:1501-1509 (1993).
Adis Newsletters abstract of Higgins, "Symposia:Amantadine:effective alternative to interferon for hepatitis C?", Inpharma, 1028:15-16. May 1996.
Henley III Raymond
Monahan Thomas J.
The Penn State Research Foundation
LandOfFree
Use of amantadine for treatment of Hepatitis C does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of amantadine for treatment of Hepatitis C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of amantadine for treatment of Hepatitis C will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1458586